Correlação neurobiológica dos sintomas pré-motores de parkinson: a origem na teoria de Braak
Barra lateral de artigos
Como Citar
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
##plugins.themes.bootstrap3.displayStats.downloads##
Societal impact
Conteúdo do artigo principal
Resumo
O diagnóstico da doença de Parkinson (DP) baseia-se nas principais manifestações motoras: bradicinesia combinada com tremor de repouso, rigidez ou ambos. Quando o diagnóstico é feito com base em sintomas clínicos motores típicos, até 60% dos neurônios dopaminérgicos da substância negra pars compacta mesencefálica já foram perdidos. A identificação de sintomas pré-motores é um marcador precoce para suspeitar do futuro aparecimento da doença, bem como da sua progressão e gravidade. A hipótese sobre a patogênese que melhor expõe a progressão da doença é a teoria de Braak. Isto se baseia no aparecimento e presença de corpos de Lewy em diferentes estruturas anatômicas, que estão representados em cada uma de suas seis etapas e podem ser a explicação biológica dos sintomas pré-motores, motores e não motores. A detecção precoce de sintomas pré-motores pode repercutir positivamente na abordagem, acompanhamento, diagnóstico e tratamento da DP. O objetivo deste artigo é identificar as abordagens neurológicas descritas pela teoria de Braak para os sintomas pré-motores da doença de Parkinson de acordo com a literatura publicada nos últimos 20 anos.
Detalhes do artigo
Referências
Rietdijk C, Perez-Pardo P, Garssen J, van Wezel R, Kraneveld A. Exploring Braak’s hypothesis of Parkinson’s disease. Front Neurol. 2017;8:37.
Opara JA, Brola W, Leonardi M, Błaszczyk B. Quality of life in Parkinson’s disease. J Med Life. 2012;5(4):375-81.
Poewe W, Seppi K, Tanner C. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013 (2017).
Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284-2303.
Zis P, Erro R, Walton CC, Sauerbier A, Chaudhuri KR. The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: A state-of-the-art systematic review. 2015;1:15013.
Mahlknecht P, Seppi K, Poewe W. The concept of prodromal Parkinson’s disease. J Parkinsons Dis. 2015;5(4):681–97.
Reichmann H. Premotor diagnosis of Parkinson’s disease. Neurosci Bull. 2017;33(5):526–34.
Rodríguez-Violante M, Zerón-Martínez R, Cervantes-Arriaga A, Corona T. Who can diagnose Parkinson’s disease first? Role of Pre-motor symptoms. Arch Med Res. 2017;48(3):221–7.
Thaler A, Alcalay RN. Diagnosis and medical management of Parkinson disease. CONTINUUM: Lifelong Learning in Neurology. 2022;28(5):1281–300.
Fullard ME, Morley JF, Duda JE. Olfactory dysfunction as an early biomarker in Parkinson’s disease. Neurosci Bull. 2017;33(5):515–25.
Barber TR, Klein JC, Mackay CE, Hu MTM. Neuroimaging in pre-motor Parkinson’s disease. NeuroImage Clin. 2017;15:215–27.
Huang H, Xu H, Luo Q, He J, Li M, Chen H, et al. Fecal microbiota transplantation to treat Parkinson’s disease with constipation: A case report. Med (United States). 2019;98(26):1-4.
Vegas-Suarez S, Paredes-Rodriguez E, Aristieta A, Lafuente JV, Miguelez C, Ugedo L. Dysfunction of serotonergic neurons in Parkinson’s disease and dyskinesia. International Review of Neurobiology [Internet]. 2019;146:259-279. Disponible en: http://dx.doi.org/10.1016/bs.irn.2019.06.013
McCann H, Cartwright H, Halliday GM. Neuropathology of α-synuclein propagation and braak hypothesis. Mov Disord. 2016;31(2):152–60.
Visanji N, Marras C. The relevance of pre-motor symptoms in Parkinsons disease. Expert Rev Neurother. 2015;15(10):1205–17.
Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: The dual syndrome hypothesis. Neurodegener Dis. 2012;11(2):79–92.
Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson’s disease. Curr Opin Neurol. 2014 Aug;27(4):434–41.
Pasquini J, Ceravolo R, Brooks DJ, Bonuccelli U, Pavese N. Progressive loss of raphe nuclei serotonin transporter in early Parkinson’s disease: A longitudinal 123I-FP-CIT SPECT study. Park Relat Disord [Internet]. 2020;77:170–5.
Pellegrini C, Antonioli L, Colucci R, Ballabeni V, Barocelli E, Bernardini N, et al. Gastric motor dysfunctions in Parkinson’s disease: Current pre-clinical evidence. Park Relat Disord. 2015;21(12):1407–14.
Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord. 2006;21(12):2062-7.
Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron. 2019;103(4):627-641.e7.
Oertel WH, Henrich MT, Janzen A, Geibl FF. The locus coeruleus: Another vulnerability target in Parkinson’s disease. Mov Disord. 2019;34(10):1423–9.
Stefani A, Högl B. Sleep in Parkinson’s disease. Neuropsychopharmacology. 2020;45(1):121-128.
Surmeier DJ. Determinants of dopaminergic neuron loss in Parkinson’s disease. FEBS J. 2018;285(19):3657-3668.
Poston KL, Cruadhlaoich MA, Santoso LF, Bernstein JD, Liu T, Wang Y, et al. Substantia nigra volume dissociates bradykinesia and rigidity from tremor in Parkinson’s disease: A 7 tesla imaging study. J Parkinsons Dis. 2020;10(2):591-604.
Zach H, Dirkx MF, Roth D, Pasman JW, Bloem BR, Helmich RC. Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease. Neurology. 2020;95(11):E1461–70.
Hallett M. Parkinson’s disease tremor: Pathophysiology. Park Relat Disord. 2012;18:S85–6.
Rong S, Li Y, Li B, Nie K, Zhang P, Cai T, et al. Meynert nucleus-related cortical thinning in Parkinson’s disease with mild cognitive impairment. Quant Imaging Med Surg. 2021;11(4):1554-1566.
Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217–31.
Salzman CD, Fusi S. Emotion, cognition, and mental state representation in amygdala and prefrontal cortex. Annu Rev Neurosci. 2010;33:173-202.
Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci. 2017;374(2016):26–31.
Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-1407.e5.
Hirayama M, Ohno K. Parkinson’s disease and gut microbiota. Ann Nutr Metab. 2021;77:28-35.
Stocchi F, Torti M. Constipation in Parkinson’s disease. International Review of Neurobiology [Internet]. 2017;134:811-826 p. Disponible en: http://dx.doi.org/10.1016/bs.irn.2017.06.003
Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem. 2016;139:318–24.
Jellinger KA. Is Braak staging valid for all types of Parkinson’s disease? J Neural Transm (Vienna). 2019;126(4):423-431.
Li J, Gu CZ, Su JB, Zhu LH, Zhou Y, Huang HY, et al. Changes in olfactory bulb volume in Parkinson’s disease: A systematic review and meta-analysis. Plos One. 2016;11(2):e0149286.
Scherfler C, Schocke MF, Seppi K, Esterhammer R, Brenneis C, Jaschke W, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson’s disease. Brain. 2006;129(Pt 2):538-42.
Tarakad A, Jankovic J. Anosmia and ageusia in Parkinson’s disease. Int Rev Neurobiol. 2017;133:541-556.
Halliday G, McCann H, Shepherd C. Evaluation of the Braak hypothesis: How far can it explain the pathogenesis of Parkinson’s disease? Expert Rev Neurother. 2012;12(6):673-86.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th Ed., Text Revision. Washington, DC: American Psychiatric Association; 2022.
Bang Y, Lim J, Choi HJ. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson’s disease: Clues to early diagnosis and effective treatment. Arch Pharm Res. 2021;44(6):588–604.
Shen CC, Tsai SJ, Perng CL, Kuo BIT, Yang AC. Risk of Parkinson disease after depression: A nationwide population-based study. Neurology. 2013;81(17):1538–44.
Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, et al. The onset of nonmotor symptoms in Parkinson’s disease (The ONSET PDStudy). Movement Disorders. 2015;30(2):229–37.
Depression [Internet]. [citado el 10 de septiembre de 2022]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/depression.
Menon B, Nayar R, Kumar S, Cherkil S, Venkatachalam A, Surendran K, et al. Parkinson’s disease, depression, and quality-of-life. Indian J Psychol Med. 2015;37(2):144–8.
Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435–50.
Postuma RB, Gagnon JF, Pelletier A, Montplaisir J. Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies. Movement Disorders. 2013;28(5):597–604.
Isaacson S, Skettini J. Neurogenic orthostatic hypotension in Parkinson’s disease: Evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag. 2014;10:169-76.
Lamotte G, Lenka A. Orthostatic hypotension in Parkinson disease: What is new? Neurol Clin Pract. 2022;12(5):e112-e115.
Palma JA, Kaufmann H. Autonomic disorders predicting Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:S94-8.
Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T. SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson’s disease with urinary dysfunction. J Neurol Sci. 2001;187(1–2):55–9.
Picillo M, Palladino R, Barone P, Erro R, Colosimo C, Marconi R, et al. The PRIAMO study: Urinary dysfunction as a marker of disease progression in early Parkinson’s disease. Eur J Neurol.
;24(6):788–95.
Hasan S, Mielke MM, Ahlskog JE, Bower J, Turcano P, Savica R. Erectile dysfunction preceding clinically diagnosed α -synucleinopathies: A case-control study in Olmsted County. Parkinsons Dis. 2019;2019:1–6.
Fereshtehnejad SM, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB. Evolution of prodromal Parkinson’s disease and dementia with Lewy bodies: A prospective study. Brain. 2019;142(7):2051-2067.
Shen Y, Liu CF. Sleep disorders in Parkinson’s disease: Present status and future prospects. Chin Med J (Engl). 2018;131(8):883-885.
Kim YE, Jeon BS. Clinical implication of REM sleep behavior disorder in Parkinson’s disease. J Parkinsons Dis. 2014;4(2):237-44.
Sateia MJ. International classification of sleep disorders-third edition: Highlights and modifications. Chest. 2014;146(5):1387-1394.
Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease. Brain. 2015;138(10):2964–73.
Taddei RN, Cankaya S, Dhaliwal S, Chaudhuri KR. Management of psychosis in Parkinson’s disease: Emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Parkinsons Dis. 2017;2017:1–18.
Reich A, Kwiatkowska D, Pacan P. Delusions of parasitosis: An Update. Dermatol Ther (Heidelb). 2019;9(4):631–8.
Torales J, García O, Barrios I, O’Higgins M, Castaldelli‐Maia JM, Ventriglio A, et al. Delusional infestation: Clinical presentations, diagnosis, and management. J Cosmet Dermatol. 2020;19(12):3183–8.
Oh M, Kim JW, Lee SM. Delusional parasitosis as premotor symptom of Parkinson’s disease: A case report. World J Clin Cases. 2022;10(9):2858–63.